<DOC>
	<DOCNO>NCT03037086</DOCNO>
	<brief_summary>MEDI-APEX non-interventional , retrospective , cohort study characterize PD-L1 expression assess clinical characteristic outcome among NSCLC patient</brief_summary>
	<brief_title>Asia PDL1 Study Among NSCLC Patients</brief_title>
	<detailed_description>MEDI-APEX non-interventional , retrospective , cohort study characterize PD-L1 expression among NSCLC patient assess clinical characteristic outcome patient specific attention EGFR , ALK , KRAS mutation . The study determine whether PD-L1 prognostic factor Asia-Pacific patient population ; The study enrol NSCLC patient disease diagnosis January 2010 December 2014 ; The patient recruit Asia-Pacific , potentially China , Japan , South Korea . A total approximately 750 patient enrol study ; around 250 NSCLC patient enrol per country .</detailed_description>
	<criteria>1 . Adult male female ( accord age majority define local regulation ) . 2 . NSCLC diagnosis 01 January 2010 31 December 2014 . 3 . FFPET collect via core needle biopsy resection available sufficient amount complete PDL1 testing . 4 . FFPET tissue sample collect NSCLC original diagnosis determination analysis ( e.g . research treatment purpose ) index date . 5 . Patients locally advance metastatic NSCLC initiate 1st line palliative chemotherapy 31 December 2014 . 1 . Patients locally advance NSCLC resectable disease treat curative intent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>NSCLC</keyword>
</DOC>